Abstract: Objective The aim of this study was to explore the application of baseline neutrophil-lymphocyte ratio(NLR),platelet count-lymphocyte ratio(PLR),monocyte-lymphocyte ratio(MLR),and pan-immune inflammation value(PIV)in the use of PD-1 inhibitors combined with chemotherapy in advanced non-small cell lung cancer(NSCLC),and establish a prognosis-related nomogram model. Methods The clinical data of 77 patients with driver gene-negative advanced NSCLC who received first-line PD-1 inhibitor combined with chemotherapy at Harbin Medical University Cancer Hospital from January 2019 to January 2021 were retrospectively analyzed.Univariate and multivariate Cox regression analysis were used to determine the independent prognostic factors of progression-free survival(PFS);A prognostic-related nomogram model was established,and the accuracy of prediction model was evaluated through consistency index. Results Multivariate Cox regression analyses showed that MLR,PIV,brain metastasis,and pleural metastasis were independent factors affecting PFS in patients with driver gene-negative advanced NSCLC(P＜0.05).The nomogram prognostic model constructed based on the Cox regression results had a good predictive ability(C-index value was 0.786,95% CI:0.721-0.851).The ROC curve showed that the combined effect of MLR and PIV in detecting the prognosis of PFS(AUC=0.717,P=0.001)was better than that of MLR(AUC=0.643)and PIV(AUC=0.640). Conclusion MLR,PIV,brain metastasis,and pleural metastasis can predict the prognosis of driver gene-negative advanced NSCLC patients treated with first-line chemotherapy combined with PD-1 inhibitors.The established nomogram model has high accuracy and clinical practicability.The predictive performance of combined detection of MLR and PIV may be better than that of separate detection of MLR and PIV.

Key words: Non-small cell lung cancer, Neutrophil-lymphocyte ratio, Platelet count-lymphocyte ratio, Monocyte-lymphocyte ratio, Pan-immune inflammatory disease value